Cadent Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 2, 2019--

Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Piper Jaffray 31 st Annual Healthcare Conference on Wednesday, December 4, 2019 at 9:30-9:50 am ET at the Lotte New York Palace.

About Cadent Therapeutics

Cadent Therapeutics is creating therapies for the treatment of movement, mood, and cognitive disorders. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor, and schizophrenia. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 2 for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Corporate and Slater Technology Fund. For more information, please visit cadenttx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191202005222/en/

CONTACT: Investors:

Maeve Conneighton,maeve@argotpartners.com

212.600.1902Media:

David Rosen,david.rosen@argotpartners.com

212.600.1902

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH MENTAL HEALTH

SOURCE: Cadent Therapeutics

Copyright Business Wire 2019.

PUB: 12/02/2019 07:00 AM/DISC: 12/02/2019 07:01 AM

http://www.businesswire.com/news/home/20191202005222/en